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It is known that angiogenesis plays an important role in bone regeneration and that release of angiogenic and
osteogenic growth factors can enhance bone formation. Multiple growth factors play key roles in processes that
lead to tissue formation/regeneration during natural tissue development and repair. Therefore, treatments
aiming to mimic tissue regeneration can benefit from multiple growth factor release, and there remains a need
for simple clinically relevant approaches for dual growth factor release. We hypothesized that mineral coatings
could be used as a platform for controlled incorporation and release of multiple growth factors. Specifically,
mineral-coated scaffolds were ‘‘dip coated’’ in multiple growth factor solutions, and growth factor binding and
release were dictated by the growth factor-mineral binding affinity. Beta tricalcium phosphate (b-TCP) scaffolds
were fabricated using indirect solid-free form fabrication techniques and coated with a thin conformal mineral
layer. Mineral-coated b-TCP scaffolds were sequentially dipped in recombinant human vascular endothelial
growth factor (rhVEGF) and a modular bone morphogenetic peptide, a mineral-binding version of bone mor-
phogenetic protein 2 (BMP2), solutions to allow for the incorporation of each growth factor. The dual release
profile showed sustained release of both growth factors for over more than 60 days. Scaffolds releasing either
rhVEGF alone or the combination of growth factors showed an increase in blood vessel ingrowth in a dose-
dependent manner in a sheep intramuscular implantation model. This approach demonstrates a ‘‘modular design’’
approach, in which a controllable biologics carrier is integrated into a structural scaffold as a thin surface coating.
Introduction
Therapeutic strategies in tissue engineering oftenrely on the delivery of growth factors in an effort to
mimic the natural microenvironments of tissue formation
and repair. Growth factors can stimulate cellular activities,
such as migration, proliferation, and differentiation to repair
or regenerate damaged tissue.1–4 An extensive number of
in vitro and in vivo studies in multiple tissue types have
shown that the delivery of single growth factors can promote
tissue regeneration.5–8 However, during natural tissue de-
velopment and regeneration, multiple growth factors play
key roles in processes that lead to tissue formation. There-
fore, treatments aiming to mimic tissue regeneration could
benefit from the release of multiple therapeutic agents. For
example, in bone tissue engineering research, recent studies
have shown that the combined delivery of osteogenic and
angiogenic growth factors enhances bone tissue regeneration
compared with single growth factor delivery.9–11 Similarly,
dual release of angiogenic and arteriogenic growth factors
can enhance stable blood vessel formation in cardiac tissue
engineering approaches.12 These studies suggest that local
release of multiple growth factors is a promising approach
for regenerative medicine.
One current strategy for dual growth factor release in-
volves loading a growth factor into microparticles by diffu-
sion followed by incorporation of the loaded microparticles
into a hydrogel containing a second growth factor.9 Another
approach involves incorporating a growth factor into poly-
mer microspheres, which are later incorporated into a hollow
scaffold coated with gelatin containing a second growth
factor.10 These techniques have been successful in demon-
strating the advantage of dual growth factor release. Although
these techniques have demonstrated proof-of-concept for
multiple growth factor delivery, clinical translation of this
concept may be facilitated by simpler techniques that can be
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applied in the operating room. Here, we report one such
simpler approach that exploits differential affinity between
growth factors and a coating material, where higher affinity
leads to slower release kinetics and lower affinity leads to
faster release kinetics. Specifically, we report controlled
sequential delivery of an angiogenic and an osteogenic
growth factor by simply ‘‘double dipping’’ a scaffold ma-
terial in growth factor solutions.
The application of bone morphogenetic proteins (BMPs)
has been the gold standard in bone tissue engineering re-
search because of the ability of BMPs to enhance bone for-
mation and facilitate healing. rhBMP-2 and BMP-2 mimics are
particularly potent osteogenic growth factors capable of re-
generating bone tissue in orthotopic13–15 and ectopic16–18 sites.
Thus, there is strong interest in delivering BMPs in a sustained
manner from tissue engineering scaffolds. However, engi-
neering of many tissue types, including bone, also relies on
creating a functional vascular network. Inadequate bone
vascularity is associated with decreased bone formation and
bone mass.19–21 Angiogenesis, the formation of new blood
vessels from pre-existing ones, is critical to deliver nutrients,
remove waste products, and provide cells and biological
mediators during fracture healing. Several factors, including
vascular endothelial growth factor (VEGF), have been identi-
fied as critical regulators of angiogenesis.22–25 Previous studies
have demonstrated that the development of a robust blood
vessel network depends on the timing, concentration gradi-
ents, and prolonged tissue exposure to proangiogenic growth
factors.26,27 Thus, there is a need for controllable sustained
VEGF release strategies to stimulate angiogenesis in tissue
engineering scaffolds. The pro-osteogenic efficacy of BMPs
and the pro-angiogenic efficacy of recombinant human VEGF
(rhVEGF) suggest that controlled delivery of these factors may
encourage vascularized bone regeneration.
In this study, we aimed to control delivery of a pro-
angiogenic and a pro-osteogenic growth factor from custom-
designed tissue engineering scaffolds using a simple ‘‘double
dipping’’ process. We hypothesized that growth factor-
scaffold binding affinity could be used to dictate the growth
factor release rate, enabling controllable incorporation and
release of multiple growth factors. Porous beta tricalcium
phosphate (b-TCP) scaffolds were fabricated using indirect
solid-free form fabrication (SFF) and then coated with a na-
noporous mineral layer using an approach described in a
variety of previous studies.3,28–34 Calcium phosphate ce-
ramics such as b-TCP are widely used as bone substitutes as
they are bioactive and osteoconductive.35 Coated scaffolds
were then loaded with two biologically active growth fac-
tors: rhVEGF protein and a modular peptide version of
BMP2 (mBMP), which contains a high affinity mineral-
binding sequence and a BMP-2-derived biologically active
sequence.36–38 We hypothesized that rhVEGF would bind
with lower affinity to mineral-coated b-TCP scaffolds re-
sulting in faster release kinetics, whereas mBMP would bind
with strong affinity resulting in slower release kinetics.
Materials and Methods
In vivo experimental design
All experimental protocols were approved by the Institu-
tional Animal Use and Care Committee. Ten Hampshire
mature female sheep, ranging in age from 2 to 5 years and
weighing between 60 and 100 kg (mean– SD, 66.4 – 8.6 kg),
were used in the study.
The experimental group consisted of scaffolds delivering
different dosages of rhVEGF (generous gift from the NIH) or
mBMP from mineral-coated b-TCP scaffolds or the combi-
nation of growth factors. The control group consisted of
mineral-coated scaffolds with no growth factor. In groups
releasing rhVEGF, 0.5, 1.0, 5.0, or 10mg were surface bound
on the mineral-coated scaffolds. A dosage of 50 mg was
bound to scaffolds releasing mBMP. The dual group had 0.5,
1.0, 5.0, or 10 mg of rhVEGF and 50 mg mBMP, respectively.
All sheep received a scaffold from each of the 10 condi-
tions (experimental and control groups). Five scaffolds were
implanted in each side of the spine, in the longissimus
lumborum, giving us a total of 10 implant sites per sheep.
Placement of the scaffold was randomized. Five sheep were
euthanized at 2 weeks and five sheep at 4 weeks, and scaf-
folds were collected for histological analysis.
b-TCP scaffold fabrication and incubation
in modified simulated body fluids
100% b-TCP ceramic suspensions were utilized in the fab-
rication of scaffolds used in this study, produced by indirect
SFF methods. In short, image-based design and three-
dimensional (3D) printing techniques were employed to
achieve scaffolds with controlled architecture: square, or-
thogonal interconnected pores with a 40% volume void frac-
tion (porosity). In their final fabricated state, scaffolds
measured 6· 4mm, with a pore size of 753– 57mm.
A 40% by volume ceramic slip was prepared by mixing as-
received b-TCP powder (Plasma Biotal) with appropriate
deflocculants and acrylate binders. The slurry was then cast
into the designed molds generated via the ModelMaker II
(Solidscape), which were removed after ceramic curing was
established. After binder burnout scaffolds were sintered in
air at 1100C for 5 h and furnace cooled.
The scaffolds were incubated at 37C in modified simulated
body fluids (mSBF) for periods of 7 days under continuous
rotation. Each scaffold was incubated in 15mL of mSBF. The
mSBF solution had a similar composition to that of human
plasma but with double the concentration of calcium and
phosphate to enhance mineral growth and was prepared as
previously reported.33 Specifically, the following reagents
were added to ddH2O heated to 37C in the order shown;
141mM NaCl, 4.0mM KCl, 0.5mM MgSO4, 1.0mM MgCl2,
4.2mMNaHCO3, 20.0mMHEPES, 5.0mM CaCl2, and 2.0mM
KH2PO4. The solution was then adjusted to a final pH of 6.8.
The mSBF solution was renewed daily in order to maintain a
consistent ionic strength throughout the experiment. The
surface morphology of the biomineral coating formed on the
b-TCP scaffolds was investigated by scanning electron mi-
croscopy. Mineral-coated b-TCP scaffolds were mounted on
aluminum stubs and sputter coated with a thin layer of gold.
Samples were imaged under high vacuum using a JEOL JSM-
6100 scanning electron microscope operating at 10 kV.
Dip coating, dual binding, and release
of rhVEGF and mBMP
Dip coating demonstration. mBMP (sequence KIP-
KASSVPTELSAISTLYL-AAAA-gEPRRgEVAgEL) was syn-
thesized by RS Synthesis. Mineral-coated scaffolds were
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dipped for *10 s in 10mL of rhodamine-labeled mBMP so-
lution at a concentration of 1mg/mL. During the dip coating
process, a movie was captured using a Nikon D90 digital
camera with a Tamron SP 60mm f/2 Macro Lens. In addi-
tion, binding over time was characterized. At 10, 20, 30, 40,
and 60min, still images of the scaffolds were captured using
a Nikon D90 digital camera with a Tamron SP 60mm f/2
Macro Lens.
Binding studies. 125I-labeled rhVEGF from Perkin Elmer
and rhodamine-labeled mBMP were used to characterize
binding of growth factors to the mineral-coated scaffolds
(Fig. 1). Binding was characterized by incubating mineral-
coated scaffolds in 400 mL of a cocktail solution of both
growth factors (rhVEGF and mBMP) for 1 h or by a two-step
incubation in 400mL of solutions containing individual
growth factors for 1 h each incubation step. The rhVEGF
solution used for binding was 1 mg/mL, 0.35% 125I-labeled
rhVEGF, and the mBMP solution, 200 mg/mL rhodamine-
labeled mBMP. The radioactivity or the fluorescence inten-
sity of the solution used for binding was measured to
determine the percentage of growth factor bound using a
Packard Cobra II Gamma Counter and a BioTek Synergy
plate reader (excitation/emission: 494/519), respectively. In
our release and in vivo studies, dual binding was performed
by the two-step incubation starting with rhVEGF and sub-
sequent mBMP incubation.
Release studies. After binding of rhVEGF and mBMP,
scaffolds were rinsed in diH2O, transferred, and incubated
in either 500 or 1000 mL of Dulbecco’s modified Eagle’s
medium and simulated body fluids (SBF, pH 7.4) at 37C
to characterize the release of mBMP and rhVEGF, respec-
tively. At the indicated time points, the radioactivity or
fluorescence intensity of the release medium was measured
using a Packard Cobra II Gamma Counter and a BioTek
Synergy plate reader (excitation/emission: 494/519),
respectively.
Preparation of coated scaffolds for implantation
Scaffolds were mineral coated as described above and ster-
ilized using ethylene oxide. Growth factor solutions were pre-
pared by mixing the appropriate amount of rhVEGF or mBMP
in phosphate-buffered saline. Growth factor solutions were
sterilized by 0.2-mL syringe filtering. Before surgery, b-TCP
scaffolds releasing single growth factor (rhVEGF or mBMP)
were incubated in 500mL of different rhVEGF solutions (5, 10,
50, and 100mg/mL) or 500mL of mBMP (100mg/mL) for 1 h.
Scaffolds from the DUAL group were incubated for 1 h in an
rhVEGF solution, 100mg/mL; rinsed and subsequently in-
cubated in 500 mL of mBMP (100mg/mL) for 1 h as well. After
binding, scaffolds were directly used in the surgery. The
rhVEGF dosages explored in this study are based on previous
studies, which indicate that 2–3mg rhVEGF released from
polymer scaffolds in a sustained manner over 2–4 weeks in-
duce angiogenesis at 2 and 4 weeks postimplantation.39,40 The
mBMP-2 dosage used in this study was more difficult to
choose since there are numerous studies releasing rhBMP2 but
fewer using the modular mineral binding version of BMP2,
and the information available in large animal models was
limited as well. However, we based our decision on previous
subcutaneous implantation studies from multiple investiga-
tors, in which*5mg BMP-2 has been released over 7–30 days
from various materials, including b-TCP,16 and resulted in a
significant induction of osteogenesis and increased the dosage
by an order of magnitude.
FIG. 1. Experimental con-
ditions used to evaluate
dual binding of rhVEGF and
mBMP. In (A), scaffolds were
dipped in a cocktail solution
of both growth factors for 1 h.
In (B), scaffolds were dipped
in an mBMP solution for 1 h,
rinsed, and dipped in an
rhVEGF solution for an ad-
ditional hour. In (C), scaffolds
were dipped in an rhVEGF
solution for 1 h, rinsed, and
dipped in an mBMP solution
for an additional hour.




Color images available online
at www.liebertpub.com/tea
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Surgical procedure
Each sheep was sedated using xylazine (0.1mg/kg, IM)
and shaved around the spine area. Ketamine (2–5mg/kg, IV)
in combination with diazepam (0.1mg/kg, IV) were given
intravenously through a cephalic catheter to induce anes-
thesia. A dose of procaine penicillin G (20,000 IU/kg, IM)
was then administered. The sheep were maintained using
isoflurane (0–4%, intratracheally). Ten implants were placed
in the longissimus lumborum (five either side of the spine) of
the sheep. A total of 10 longitudinal incisions of *20mm in
length were performed in either sides of the spine. A
‘‘pocket’’ was formed in the longissimus lumborum. Each
pocket spaces 50mm on each side. Scaffolds were placed in
each muscle pocket, and the muscle was sutured and closed
with a nonabsorbable suture that also served as a reference
point for later implant retrieval. The subcutaneous tissue and
skin were closed in a routine manner. After the surgery, a
second dose of procaine penicillin G (20,000 IU/kg, IM) was
given. Phenylbutazone (4.4mg/kg, PO q24hr for 3 days) was
administered for pain beginning the same day at the surgery
and continued for 3 days.
Implant retrieval and scaffold preparation for histology
Animals were euthanized using sodium pentobarbital
(Beuthanasia) 200mg/kg, IV (n = 5 per time point), and the
longissimus lumborum removed at 2 and 4 weeks. The
scaffolds collected at the 2 weeks time point were fixed in
Zamboni’s fixative (Newcomer Supply) for 48 h, decalcified
in EDTA/sucrose for 7 days, paraffin embedded, and sec-
tioned. Two-week tissue sections were stained for von
Willebrand factor (vWF) using a Lab Vision autostainer
(serial# LVMA-LV1.3-0237) and imaged with a Nikon Opti-
phot microscope and an AxioCam (Zeiss) digital camera.
Blood vessels, indicated by vWF staining, were counted
manually at 10 ·magnification in the pores of the scaffold
area and normalized to tissue area with the use of AxioVi-
sion 4.7 software.
The scaffolds collected at the 4 weeks time point were fixed
in 10% neutral buffered formalin, dehydrated in an ethanol
series, and infiltrated with methylmethacrylate monomer.
Following polymerization, samples were sectioned using a
Leica SP1600-Saw Microtome. Resulting sections were stained
with Goldner’s Trichrome and Sanderson’s Rapid Bone Stain
(Surgipath) and counterstained with acid fuchsin (Sigma).
Sections from 2 and 4 weeks were also stained with hema-
toxilyn and eosin and were imaged using a Nikon Optiphot
microscope.
Results
Porous b-TCP scaffolds were fabricated via 3D printing,
an indirect SFF technique, with controlled periodic porous
architecture (Fig. 2a). Incubation of b-TCP scaffolds in mSBF
resulted in the formation of a continuous mineral layer on
the material (Fig. 2b, c). The mineral displayed a plate-like
nanostructure (Fig. 2d) consistent with a hydroxyapatite
coating as previously characterized.3,34,41
Dip coating scaffolds in a solution of rhodamine-labeled
mBMP (1mg/mL) results in binding of the growth factor
within seconds (Fig. 3a and Supplementary Movie S1). Fur-
ther evaluation of binding over time suggested that the
amount of growth factor bound may increase with longer
incubation times (Fig. 3b). Both rhVEGF and mBMP could be
bound to mineral-coated scaffolds after a simple 2-step dip-
ping process (Fig. 1). When scaffolds were dipped in a so-
lution containing a cocktail of both rhVEGF (1mg/mL) and
mBMP (200mg/mL), 73%– 11% of mBMP bound to the
mineral coating, whereas rhVEGF did not bind (Fig. 4a). This
result indicates that mBMP’s higher binding affinity can in-
hibit rhVEGF binding. Similarly, when scaffolds were first
dipped in an mBMP containing solution, followed by an
FIG. 2. (a) b-TCP scaffold
fabricated via SFF. (b–c) In-
cubation of b-TCP scaffolds
in mSBF for 7 days resulted in
the formation of a continuous
coating. (d) The morphology
of the mineral displayed a
plate-like nanostructure
characteristic of hydroxyapa-
tite. b-TCP, beta tricalcium
phosphate; mSBF, modified
simulated body fluids; SFF,
solid-free form fabrication.
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rhVEGF containing solution, 87%–2% of mBMP bound but we
still observed no binding of rhVEGF (Fig. 4a). However, when
scaffolds were first dipped in an rhVEGF solution, followed by
an mBMP containing solution, 14%–3% of rhVEGF bound and
83%–1% of mBMP bound to the mineral coating (Fig. 4a).
Thus, rhVEGF and mBMP can be loaded into the same mineral
coating, but only by first incubating in rhVEGF followed by
mBMP. We next characterized this ‘‘double dipping’’ process
by exploring whether rhVEGF was competitively removed
during the second dipping step (i.e., during mBMP binding).
Our results demonstrated that the amount of bound rhVEGF
was not significantly decreased after the mBMP binding step,
indicating no competitive removal (Fig. 4b).
Release of the bound rhVEGF and mBMP was sustained
for over 60 days in either the cell culture medium or SBF.
The release profile over a 65 day period was strongly de-
pendent on the mineral-binding affinity, as the mBMP
molecule (designed for high affinity mineral binding) re-
leased less than 15%, whereas the rhVEGF (with no specific
mineral-binding component) released over 60% (Fig. 5). The
actual amount of growth factor released at different time
points is shown in Supplementary Tables S1 and S2 for each
buffer. Although the percentage of mBMP is lower from
that of rhVEGF, the total amount of mBMp released is
higher as a higher dosage (biologically relevant) of mBMP
was chosen. The amount of released growth factor also
depended on the buffer used for the release study. In SBF,
scaffolds released less total growth factor (35% – 0.3% of
rhVEGF and 9% – 0.1% of mBMP over 60 days) than in the
cell culture medium (62% – 0.5% of rhVEGF and 14% – 0.5%
of mBMP over 60 days) (Fig. 5).
Scaffolds releasing rhVEGF stimulated an increase in
blood vessel density within the scaffolds, and the stimulatory
effect of released rhVEGF was dose dependent. The density
of blood vessels within scaffolds releasing rhVEGF at dos-
ages of 1, 5, and 10 mg significantly increased compared to
blank scaffolds (Fig. 6). Similarly, the scaffolds releasing both
rhVEGF and mBMP demonstrated an rhVEGF-dependent
increase in blood vessel density (Fig. 7), and the rhVEGF-
stimulated blood vessel infiltration was not significantly
influenced by the release of mBMP (Fig. 8). The scaffolds
were well tolerated and engendered no apparent immune
reaction, and the presence of rhVEGF and mBMP did not
influence the implant response. At 2 weeks, a thin fibrous
capsule was observed around the outside of each of the
scaffolds, as well as around the individual pores (Fig. 9). The
release of mBMP resulted in significantly increased tissue
infiltration into the scaffold at 4 weeks (Fig. 10) but did not
stimulate apparent ectopic bone formation.
FIG. 3. Visual demonstration of dip coating process. (a)
Scaffolds dipped in a 1mg/mL mBMP solution for 10 s
changed color demonstrating binding of rhodamine-labeled
mBMP to the mineral-coated scaffold (see Supplementary
Movie S1). (b) Characterization of binding over time at the
mBMP concentration used for the in vivo studies demon-
strated that the amount of growth factor bound depends on
the time scaffolds are incubated in the growth factor solution.
Color images available online at www.liebertpub.com/tea
FIG. 4. Characterization of dual binding of rhVEGF and mBMP to mineral-coated scaffolds. (a) Scaffolds were dipped in a
cocktail of rhVEGF and mBMP, in rhVEGF followed by mBMP, and in rhVEGF followed by mBMP. The percentage of
growth factor bound was characterized in (a) for all these conditions. Dual growth factor binding was obtained after the
sequential dipping of scaffolds in rhVEGF initially, followed by mBMP. (b) The amount of rhVEGF bound to the scaffolds
after the first dipping was not significantly changed during the second dipping step.
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Discussion
The objective of this study was to deliver angiogenic and
osteogenic growth factors using a simple adaptable double
dipping process. We hypothesized that two different growth
factors would bind to mineral-coated scaffolds and would
exhibit sustained release kinetics dependent on the growth
factor-scaffold binding affinity. To address this hypothesis,
we chose two growth factors: one with relatively low mineral
binding affinity (rhVEGF) and one with uniquely high
mineral binding affinity (mBMP). The surface of the mineral
coating was highly porous (Fig. 2d) and contained charged
calcium and phosphate components. Therefore, we hypoth-
esized that the coating would be capable of efficiently
binding growth factors via electrostatic interactions and
would release growth factors for extended periods of time.
We achieved binding of rhVEGF and mBMP by sequen-
tially dipping scaffolds in rhVEGF and mBMP solutions,
respectively. The mBMP was engineered to contain a mineral
binding domain that strongly interacts with the mineral
surface. The affinity of this engineered peptide was charac-
terized previously by Lee et al. and is due to the presence
of an osteocalcin-inspired peptide sequence containing three
g-carboxylated glutamic acid resides that coordinate with
calcium ions in the mineral crystal lattice.42 Previous studies
have demonstrated an ability to systematically vary the
FIG. 5. Dual release of
rhVEGF and mBMP in (a)
SBF and (b) DMEM. Release
of both growth factors was
sustained for over 2 months.
The release of both growth
factors was slower in SBF,
which contains the same ionic
constituents of blood plasma.
DMEM, Dulbecco’s modified
Eagle’s medium.
FIG. 6. In vivo effect of released rhVEGF from single growth factor releasing scaffolds. rhVEGF release enhanced blood
vessel ingrowth (black arrows) 2 weeks after implantation. (a–e) vWF immunostaining of blood vessels within sections of
implanted b-TCP scaffolds releasing (a) No rhVEGF; (b) 0.5 mg rhVEGF; (c) 1.0 mg rhVEGF; (d) 5mg rhVEGF; and (e) 10mg
rhVEGF. Positive vWF staining is brown, and circular vWF staining represents a blood vessel. (f) Quantification of the
number of blood vessels within the pores of the scaffold. *p< 0.003 relative to the no growth factor condition. Scale bars =
100 mm. vWF, von Willebrand factor. Color images available online at www.liebertpub.com/tea
2082 SUA´REZ-GONZA´LEZ ET AL.
peptide-mineral binding affinity and release.42,43 Here, we
chose to use the highest affinity mineral-binding sequence to
extend mBMP release over a much longer time frame than
rhVEGF release, as a clear demonstration of our dual release
concept. Analysis of the release profile of the growth factors
from mineral-coated b-TCP biomaterials showed that both
rhVEGF and mBMP can be released for over 60 days in
different mediums (Fig. 5). Growth factor release from min-
eral coatings is influenced by the surrounding solution
characteristics. Since SBF is supersaturated with calcium and
phosphate ions, mineral dissolution and reprecipitation can
both occur. As the coating dissolves in SBF, the released
protein may re-bind to existing or newly formed mineral or
may become encapsulated within a growing mineral coating.
Each of these scenarios would result in slower protein release
kinetics. These mechanisms for decreased protein release
would likely be less prevalent in the cell culture medium as
it has a lower concentration of calcium and phosphate
ions when compared to SBF. As expected, mBMP released
with slower release kinetics (14%– 1.6% over 60 days)
when compared to rhVEGF release kinetics (62%– 1.5% over
60 days).
Dual growth factor release has been explored successfully
by others in previous studies.9,10,44 Patel et al. released
rhVEGF and BMP2 from gelatin microparticles into a critical-
sized rat calvarial defect.9 This approach resulted in signifi-
cantly higher bone formation in the dual release group, but
loading of the growth factor into gelatin by diffusion re-
quired a 20 h incubation step.9 Similarly, Kempen et al. used
dual release of rhVEGF and BMP2 to enhance ectopic bone
formation in rats.10 The Kempen et al. study created PLG
microspheres loaded with BMP2 and embedded them in a
scaffold that was coated with a VEGF-loaded gelatin hy-
drogel.10 These studies clearly demonstrate the impact of
dual growth factor delivery. Here, we endeavored to create a
relatively simple and adaptable approach for sustained re-
lease of multiple bioactive growth factors based on scaffold
binding affinity. Mineral-coated scaffolds were dipped in
growth factor solutions intraoperatively—immediately be-
fore scaffold implantation. The amount of rhVEGF bound to
the mineral coating was not significantly decreased during
the subsequent dipping in the mBMP solution (Fig. 4b). In-
terestingly, when scaffolds were incubated in mixed solu-
tions with both rhVEGF and mBMP, or mBMP followed by
rhVEGF, there was negligible rhVEGF binding. We can at-
tribute this to more rapid and efficient mBMP binding rela-
tive to rhVEGF. Therefore, this intraoperative ‘‘double
dipping’’ process could be used for dual growth factor in-
corporation, but only in the case where the lower affinity
binder (rhVEGF) was added before the higher affinity binder
(mBMP).
Previous studies by our group have successfully used
mineral coatings on various devices for the release of bio-
active single growth factors in vitro and in vivo, suggesting
growth factors are not denatured.3,43,45 In a study by Suarez-
Gonzalez et al., rhVEGF released from mineral-coated b-TCP
FIG. 7. In vivo effect of released rhVEGF from dual growth factor releasing scaffolds. rhVEGF release enhanced blood vessel
ingrowth (black arrows) 2weeks after implantation. (a–d)vWF immunostaining of blood vesselswithin sections of implantedb-TCP
scaffolds releasing (a) No rhVEGF; (b) 0.5mg rhVEGF; (c) 1.0mg rhVEGF; (d) 10mg rhVEGF. Positive vWF staining is brown, and
circular vWF staining represents a blood vessel. (e) Quantification of the number of blood vessels within the pores of the scaffold.
*p<0.009 relative to the no growth factor condition. Scale bars=100mm. Color images available online at www.liebertpub.com/tea
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scaffolds similar to those explored in our current study was
capable of binding to VEGF antibody and was capable of
promoting human umbilical vein endothelial cell (HUVEC)
proliferation in vitro. VEGF-induced HUVEC proliferation
required a lower concentration of released rhVEGF when
compared to bolus rhVEGF.3 Lee et al. delivered basic fi-
broblast growth factor (bFGF) from mineral-coated sutures
in a chronic rotator cuff repair model in sheep and the local
release of bFGF improved the load at failure of the repaired
tendon.46 Lu et al. delivered mBMP from mineral-coated
bioresorbable interference screws in a sheep tendon-bone
healing model and demonstrated that the group receiving
mBMP had improved histological scores of early tendon-
bone healing.45 Taken together, these studies and others
suggest that the mechanism of growth factor-mineral bind-
ing and subsequent release maintains the growth factor bi-
ological activity and serves as a simple and perhaps broadly
applicable technique.3,34,41,45,47,48
Importantly, mineral coatings can be grown on b-TCP
scaffolds fabricated via indirect SFF. SFF could prove highly
useful for the construction of scaffolds possessing patient-
specific anatomies and interior porous architectures derived
from computational design optimizations. This fabrica-
tion technique allows precise control over properties, such as
pore size, porosity, permeability, and stiffness.49 Control
over these characteristics may enhance cell infiltration and
mass transport of nutrients and metabolic waste throughout
the scaffold. We observed tissue infiltration within the pores
of b-TCP scaffolds implanted after 2 and 4 weeks (Figs. 9 and
10). This is consistent with previous work with other porous
implants in which fibrous and/or bone tissue inflitration
has been observed.35,50 At both 2 and 4 weeks, we observed
a thin fibrous capsule around the outer surface of the scaf-
fold as well as around the pores (Fig. 9). Formation of a thin
capsule has been observed in other studies as well and
suggests a mild foreign body reaction. The potential to
mineral coat structurally optimized b-TCP scaffolds allows
for ‘‘modular design’’ of scaffolds, in which the biologics
carrier (i.e., the coating) is integrated into the structural de-
vice without negatively impacting scaffold physical properties.
This type of modular design approach may be particularly
useful for design of bone tissue engineering scaffolds, in which
there is a clear need for optimized physical and biological
properties.51
Release of rhVEGF from b-TCP scaffolds resulted in an
increase in blood vessel tissue ingrowth (Figs. 6 and 7). The
number of blood vessels increased as the dosage of rhVEGF
increased from 0.5 to 10 mg (Fig. 6). The same effect of re-
leased rhVEGF in blood vessel tissue ingrowth was observed
in the dual releasing scaffolds (Fig. 7), indicating that the
presence of mBMP does not affect the bioactivity of the re-
leased rhVEGF in vivo. mBMP enhanced tissue infiltration to
the scaffold suggesting improved tissue-material interac-
tions, but mBMP did not induce any apparent ectopic bone
FIG. 8. Comparison of blood vessel number and area be-
tween scaffolds releasing single versus dual growth factor.
(a) Blood vessel infiltration was not significantly different
between single and dual releasing scaffolds in the 0.5 and
10 mg rhVEGF. There was statistical significance at the 1mg
dose (p= 0.03). (b) Blood vessel area was not significantly
different ( p > 0.18), suggesting that the presence of mBMP
did not influence the effect of rhVEGF in blood vessel infil-
tration and the area of the blood vessels formed.
FIG. 9. H&E staining of
sections of scaffolds at 2
weeks. (a) Formation of a thin
fibrous capsule was observed
in all conditions. This image
is from an mBMP releasing
scaffold, but all treatment
groups showed the formation
of a thin fibrous capsule. (b)
Fibrous tissue infiltration was
also observed in all condi-
tions. The image presented is
from the no growth factor
group. H&E, hematoxylin
and eosin. Color images
available online at www
.liebertpub.com/tea
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formation in this study (Fig. 10). Although our previous
studies have shown robust orthotopic bone formation in
response to mBMP,47 ectopic bone formation was not
observed in any of the groups releasing mBMP in this study.
There are numerous possible reasons for this observation.
Previous studies that have used the BMP2 mimicking
peptide portion of mBMP to stimulate ectopic bone forma-
tion used dosages on the order of milligrams (3mg) in rats.37
From the in vitro release data, we observed slow release of
mBMP, and the initial amount of mBMP loaded into scaf-
folds was 50mg. Thus, it is possible that the mBMP amount
released in vivo was not sufficient to elicit a response in a
sheep intramuscular implantation model. It is also possible
that high densities of mBMP are required for biological ac-
tivity. mBMP is a monomer and may require high epitope
presentation to promote receptor multimerization and acti-
vation. Higher dosages of mBMP, high-density mBMP pre-
sentation on a biomaterial, prolonged time points for implant
retrieval, and/or the use of mBMP in an orthotopic defect
may be promising approaches for future studies. However,
the lack of ectopic bone formation induced in the current
study may be desirable when combined with our previous
observations of orthotopic bone formation in response to
mBMP in sheep models.45,47 In particular, the ability of mBMP
to stimulate orthopic bone formation without stimulating ec-
topic bone formation could be advantageous, as heterotopic
bone growth has led to significant side effects during clinical
use of bone growth factors, such as rhBMP2.52,53 Further
studies will be needed to more completely define the effects of
mBMP in ectopic versus orthotopic sites.
Conclusions
This study presented a simple and adaptable approach for
dual growth factor release from b-TCP scaffolds formed via
solid free-form fabrication. Scaffolds were mineral-coated via
incubation in mSBF, and the coating was used as a template
for growth factor binding and release. In the present study,
the simple approach used for dual binding consisted of se-
quentially dip coating mineral scaffolds in growth factor
solutions. This approach allowed for control over the dosage
by changing the growth factor concentration in the solution
used for the dip coating process. Both growth factors tested
were released in a sustained manner, with release kinetics
commensurate with scaffold-growth factor affinity. When
implanted in vivo, intramuscularly in sheep, rhVEGF stimu-
lated an increase in blood vessel density. The effect was
enhanced as the dosage of rhVEGF increased, and the effect
was not influenced by simultaneous release of mBMP.
mBMP stimulated a significant increase in tissue infiltration
in the scaffold but did not stimulate ectopic bone formation.
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